Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACTU Actuate Therapeutics	$10.31 -0.2%	$8.66	$5.51 ▼ $11.73	$202.28M	N/A	47,910 shs	18,708 shs
ATNM Actinium Pharmaceuticals	$1.65 +0.6%	$1.46	$1.03 ▼ $8.64	$51.47M	-0.24	500,299 shs	181,392 shs
AVTE Aerovate Therapeutics	$7.03 -4.0%	$56.30	$43.75 ▼ $884.98	$203.77M	0.95	18,650 shs	398,026 shs
DRUG Bright Minds Biosciences	$27.44 -5.4%	$32.07	$0.93 ▼ $79.02	$193.29M	-5.32	825,050 shs	39,598 shs

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACTU Actuate Therapeutics	-0.19%	-2.74%	+15.20%	+46.66%	+1,030,999,900.00%
ATNM Actinium Pharmaceuticals	+0.61%	-9.84%	+25.95%	+48.65%	-83.16%
AVTE Aerovate Therapeutics	0.00%	-5.26%	-92.51%	-91.73%	-98.82%
DRUG Bright Minds Biosciences	-5.41%	-15.47%	-16.11%	-18.50%	+2,388.89%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACTU Actuate Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ATNM Actinium Pharmaceuticals	1.3054 of 5 stars	3.4	0.0	0.0	0.0	1.7	0.0	0.6
AVTE Aerovate Therapeutics	0.9312 of 5 stars	3.0	0.0	0.0	0.0	0.6	1.7	0.6
DRUG Bright Minds Biosciences	2.796 of 5 stars	3.6	4.0	0.0	0.0	2.6	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACTU Actuate Therapeutics	3.00	Buy	$20.50	98.84% Upside
ATNM Actinium Pharmaceuticals	2.75	Moderate Buy	$4.00	142.42% Upside
AVTE Aerovate Therapeutics	2.00	Hold	$78.75	1,020.20% Upside
DRUG Bright Minds Biosciences	3.25	Buy	$83.25	203.39% Upside

Current Analyst Ratings Breakdown

Latest ATNM, DRUG, AVTE, and ACTU Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/21/2025	DRUG Bright Minds Biosciences	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$80.00 ➝ $80.00
5/13/2025	DRUG Bright Minds Biosciences	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy
5/13/2025	DRUG Bright Minds Biosciences	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/13/2025	DRUG Bright Minds Biosciences	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy
5/12/2025	ATNM Actinium Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.00 ➝ $4.00
5/7/2025	DRUG Bright Minds Biosciences	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$80.00
4/28/2025	ATNM Actinium Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.00 ➝ $4.00
4/22/2025	ACTU Actuate Therapeutics	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$21.00
4/1/2025	ATNM Actinium Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.00 ➝ $4.00
3/25/2025	ATNM Actinium Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.00 ➝ $4.00
3/18/2025	ATNM Actinium Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.00 ➝ $4.00

(Data available from 5/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACTU Actuate Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A
ATNM Actinium Pharmaceuticals	$81K	635.47	N/A	N/A	$1.31 per share	1.26
AVTE Aerovate Therapeutics	N/A	N/A	N/A	N/A	$3.96 per share	N/A
DRUG Bright Minds Biosciences	N/A	N/A	N/A	N/A	$5.86 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACTU Actuate Therapeutics	-$24.75M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
ATNM Actinium Pharmaceuticals	-$48.82M	-$1.39	N/A	N/A	N/A	N/A	-100.85%	-47.89%	N/A
AVTE Aerovate Therapeutics	-$75.52M	-$1.70	N/A	N/A	N/A	N/A	-90.19%	-77.47%	8/11/2025 (Estimated)
DRUG Bright Minds Biosciences	-$2.06M	-$0.36	N/A	N/A	N/A	N/A	-5.85%	-5.68%	8/13/2025 (Estimated)

Latest ATNM, DRUG, AVTE, and ACTU Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2025	Q1 2025	ACTU Actuate Therapeutics	-$0.26	-$0.32	-$0.06	-$0.32	N/A	N/A
5/15/2025	Q2 2025	DRUG Bright Minds Biosciences	-$0.39	-$0.29	+$0.10	-$0.29	N/A	N/A
4/25/2025	Q4 2024	AVTE Aerovate Therapeutics	-$10.50	-$3.15	+$7.35	-$0.09	N/A	N/A
3/27/2025	Q4 2024	AVTE Aerovate Therapeutics	-$6.65	-$6.65	N/A	-$0.19	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACTU Actuate Therapeutics	N/A	N/A	N/A	N/A	N/A
ATNM Actinium Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
AVTE Aerovate Therapeutics	N/A	N/A	N/A	N/A	N/A
DRUG Bright Minds Biosciences	N/A	N/A	N/A	N/A	N/A

Latest ATNM, DRUG, AVTE, and ACTU Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
4/9/2025	AVTE Aerovate Therapeutics		$84.00		4/29/2025	4/25/2025	4/28/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACTU Actuate Therapeutics	N/A	1.68	1.68
ATNM Actinium Pharmaceuticals	N/A	10.25	10.25
AVTE Aerovate Therapeutics	N/A	8.78	8.78
DRUG Bright Minds Biosciences	N/A	126.01	11.31

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACTU Actuate Therapeutics	N/A
ATNM Actinium Pharmaceuticals	27.50%
AVTE Aerovate Therapeutics	N/A
DRUG Bright Minds Biosciences	40.52%

Insider Ownership

Company	Insider Ownership
ACTU Actuate Therapeutics	69.34%
ATNM Actinium Pharmaceuticals	6.00%
AVTE Aerovate Therapeutics	24.90%
DRUG Bright Minds Biosciences	42.66%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACTU Actuate Therapeutics	10	19.62 million	N/A	N/A
ATNM Actinium Pharmaceuticals	30	31.20 million	29.32 million	Optionable
AVTE Aerovate Therapeutics	20	28.99 million	21.69 million	Optionable
DRUG Bright Minds Biosciences	N/A	7.04 million	4.04 million	Not Optionable

ATNM, DRUG, AVTE, and ACTU Headlines

Recent News About These Companies

What is Chardan Capital's Forecast for DRUG FY2025 Earnings?

May 27 at 1:50 AM | marketbeat.com

HC Wainwright Issues Pessimistic Outlook for DRUG Earnings

May 27 at 1:35 AM | marketbeat.com

HC Wainwright Has Bearish Forecast for DRUG Q3 Earnings

May 26 at 1:36 AM | americanbankingnews.com

Bright Minds Biosciences (NASDAQ:DRUG) Downgraded to "Sell" Rating by Wall Street Zen

May 25 at 3:57 AM | americanbankingnews.com

Bright Minds Biosciences (NASDAQ:DRUG) Cut to "Sell" at Wall Street Zen

May 24, 2025 | marketbeat.com

Chardan Capital Reiterates Buy Rating for Bright Minds Biosciences (NASDAQ:DRUG)

May 23, 2025 | marketbeat.com

Bright Minds Biosciences (NASDAQ:DRUG) Earns "Buy" Rating from Chardan Capital

May 23, 2025 | americanbankingnews.com

Point72 Asset Management L.P. Buys Shares of 135,189 Bright Minds Biosciences Inc. (NASDAQ:DRUG)

May 22, 2025 | marketbeat.com

Bright Minds Biosciences Announces Featured Speakers for its Absence Epilepsy Virtual R&D Day on May 20, 2025

May 20, 2025 | globenewswire.com

Janus Henderson Group PLC Buys New Position in Bright Minds Biosciences Inc. (NASDAQ:DRUG)

May 18, 2025 | marketbeat.com

FY2025 Earnings Forecast for DRUG Issued By Chardan Capital

May 18, 2025 | americanbankingnews.com

Bright Minds Biosciences (NASDAQ:DRUG) Upgraded to Strong-Buy at Cantor Fitzgerald

May 17, 2025 | marketbeat.com

Bright Minds Biosciences (DRUG) to Release Earnings on Wednesday

May 16, 2025 | marketbeat.com

TD Cowen Begins Coverage on Bright Minds Biosciences (NASDAQ:DRUG)

May 15, 2025 | marketbeat.com

TD Cowen Initiates Coverage of Bright Minds Biosciences (DRUG) with Buy Recommendation

May 14, 2025 | msn.com

Bright Minds Biosciences Announces Positive Findings from its DBA/2 Mouse Model Study Evaluating BMB-101

May 14, 2025 | finance.yahoo.com

Chardan Capital Initiates a Buy Rating on Bright Minds Biosciences (DRUG)

May 9, 2025 | theglobeandmail.com

Bright Minds Biosciences Inc. (NASDAQ:DRUG) Receives Consensus Rating of "Buy" from Brokerages

May 9, 2025 | marketbeat.com

Chardan Capital Begins Coverage on Bright Minds Biosciences (NASDAQ:DRUG)

May 9, 2025 | marketbeat.com

Epilepsy-Focused Bright Minds Biosciences A High-Risk, High-Reward Play, Analyst Initiates With Over 150% Stock Upside

May 7, 2025 | benzinga.com

Chardan Capital Initiates Coverage of Bright Minds Biosciences (DRUG) with Buy Recommendation

May 7, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Qualcomm Is 5x Cheaper Than AMD, But Won’t Be for Long
By Sam Quirke | May 13, 2025
View Qualcomm Is 5x Cheaper Than AMD, But Won’t Be for Long
Why D-Wave's Project With Davidson Is a Game-Changer For Quantum
By Nathan Reiff | April 30, 2025
View Why D-Wave's Project With Davidson Is a Game-Changer For Quantum
Super Micro Computer Stock Clears New Path Higher on Saudi Orders
By Gabriel Osorio-Mazilli | May 22, 2025
View Super Micro Computer Stock Clears New Path Higher on Saudi Orders
Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 Earnings
By Thomas Hughes | May 27, 2025
View Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 Earnings
Analysts Think These Stocks Could More Than Double in Value
By Nathan Reiff | May 23, 2025
View Analysts Think These Stocks Could More Than Double in Value

ATNM, DRUG, AVTE, and ACTU Company Descriptions

Actuate Therapeutics NASDAQ:ACTU

$10.31 -0.02 (-0.19%)

Closing price 05/27/2025 04:00 PM Eastern

Extended Trading

$10.38 +0.07 (+0.68%)

As of 05/27/2025 04:39 PM Eastern

Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company's lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. The company was incorporated in 2015 and is based in Fort Worth, Texas.

Actinium Pharmaceuticals NYSE:ATNM

$1.65 +0.01 (+0.61%)

Closing price 05/27/2025 04:00 PM Eastern

Extended Trading

$1.64 0.00 (-0.30%)

As of 05/27/2025 04:04 PM Eastern

Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). The company focuses on advancing its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients. In addition, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies. Its Iomab-ACT, a next generation conditioning candidate, is being developed for improving patient access and outcomes for curative cell and gene therapies. Further, the company's research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company holds approximately 235 patents and patent applications, including various patents related to the manufacture of the isotope Ac-225 in a cyclotron. The company is based in New York, New York.

Aerovate Therapeutics NASDAQ:AVTE

$7.03 -0.29 (-3.96%)

As of 05/23/2025

Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. The company was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

Bright Minds Biosciences NASDAQ:DRUG

$27.44 -1.57 (-5.41%)

Closing price 05/27/2025 04:00 PM Eastern

Extended Trading

$28.00 +0.56 (+2.04%)

As of 05/27/2025 07:56 PM Eastern

Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder. The company also developing BMB-202 for the treatment of depression, anxiety, and PTSD; and BMB-201 for the treatment of anxiety. It has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. Bright Minds Biosciences Inc. was founded in 2017 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time